证券代码：301239 证券简称：普瑞眼科 成都普瑞眼科医院集团股份有限公司 投资者关系活动记录表 编号：2025-001 | 投资者关系活动 | | □特定对象调研□分析师会议 | | --- | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | | □新闻发布会□路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2025 年 5 月 19 日 (周一) 下午 15:00~16:00 | | | 地点 | 网络远程 | | | 上市公司接待人 | 董事长：徐旭阳 | | | 员姓名 | 副总经理、董事会秘书：金亮 | | | | 财务负责人：杨国平 | | | | 独立董事：邹欢 | | | | 保荐代表人：李沁杭 1、请问公司如何看待行业未来的发展前景？ | | | | 答：眼科医疗服务行业未来发展机遇与挑战并存。首先，眼科市 场规模持续扩大。随着老龄化加速，白内障患者增多，手术市场 | | | | 规模将不断扩大；青少年近视防控形势严峻，医学视光市 ...

Core Insights - The company reported a revenue of 20.983 billion yuan for 2024, a year-on-year increase of 3.02%, and a net profit attributable to shareholders of 3.556 billion yuan, up 5.87% [1] - In Q1 2025, the company achieved a revenue of 6.026 billion yuan, representing a year-on-year growth of 15.97%, and a net profit of 1.050 billion yuan, an increase of 16.71% [1] - The company demonstrated strong operational resilience despite a slowdown in the ophthalmology industry, with outpatient visits reaching 16.9407 million, a 12.14% increase, and surgical procedures totaling 1.2947 million, up 9.38% [1] Business Performance - The company’s refractive project revenue was 7.603 billion yuan, growing by 2.31%, while optical project revenue reached 5.279 billion yuan, increasing by 6.42% [1] - Cataract surgery revenue was 3.489 billion yuan, up 4.87%, and anterior segment surgery revenue was 1.898 billion yuan, growing by 5.95% [1] - Posterior segment surgery revenue amounted to 1.499 billion yuan, reflecting an 8.22% increase [1] Strategic Expansion - The company is enhancing its ophthalmology network, having established the Changsha Medical Center in 2024 to improve medical education and research capabilities [2] - Regional eye centers in Shanghai and Nanning have been completed, while facilities in Hubei, Anhui, Shenyang, and Guizhou are operational, and Beijing Aier Yingzhi is under construction [2] - The acquisition of 87 medical institutions has further strengthened the grassroots hospital network, and the company has entered the UK ophthalmology market through the acquisition of Optimax Group [2] Financial Forecast - Revenue projections for 2025-2027 are 23.681 billion, 27.084 billion, and 31.154 billion yuan, with corresponding growth rates of 12.86%, 14.37%, and 15.03% [3] - Net profit forecasts for the same period are 4.115 billion, 4.761 billion, and 5.615 billion yuan, with growth rates of 15.71%, 15.70%, and 17.95% [3] - The company is expected to maintain a strong position in the ophthalmology service sector, with a three-year CAGR of 16.45% [3]

证券代码：301267 证券简称：华厦眼科 华厦眼科医院集团股份有限公司 投资者关系活动记录表 编号：2025-002 | | 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | --- | --- | | | □新闻发布会 □路演活动 | | | □现场参观 | | 投资者关系活动类别 | 其他：中金公司、中信建投、中信证券、国泰海通、华泰证 | | | 券、兴业证券、申万宏源、国联民生、西南证券、广发证券、 | | | 华创证券、华安证券、东北证券、招商证券、华福证券、信达 | | | 证券、方正证券、天风证券、民生证券、国盛证券组织的电话 | | | 会议 | | 参与单位名称及人员 | 共计 名投资者参与交流，参会人员名单详见附件。 80 | | 姓名 | | | 时间 | 年 月 日 2025 4 28 15:30-16:30 | | 地点 | 公司会议室 | | | 陈凤国先生 董事 | | | 李晓峰先生 董事、副总经理 | | 上市公司接待人员 姓名 | 张志勇先生 副总经理 | | | 陈鹭燕女士 财务总监 | | | 曹乃恩先生 董事会秘书 | | 投资者关系活动主要 | 一 ...

Investment Rating - The report maintains a "Recommended" rating for the company [3][5]. Core Views - The company is expected to see growth in its refractive surgery segment due to an increase in average customer spending, while the cataract segment is anticipated to recover from a high base effect starting in May 2024 [2]. - Cost reduction and efficiency improvements are projected to lead to a decrease in expenses, with a gross margin of 48.02% in Q1 2025 [2]. - The company is positioned as a leading player in the ophthalmology medical service sector, with strengthening brand power and operational resilience [3]. Financial Forecasts - Revenue projections for 2025-2027 are estimated at 23.09 billion, 26.07 billion, and 29.22 billion yuan, with corresponding growth rates of 10.0%, 12.9%, and 12.1% [3][4]. - Net profit attributable to shareholders is forecasted to be 4.03 billion, 4.70 billion, and 5.43 billion yuan for the same period, with growth rates of 13.3%, 16.6%, and 15.6% respectively [3][4]. - The report provides a PE ratio forecast of 30, 26, and 23 for the years 2025, 2026, and 2027 [3][4].